Showing results (261-270 of 427) with videos related to

Sort By:
Pageof 43
Annals of Surgical Oncology|November 7, 2015
Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020)Faina Nakhlis, Lauren Gilmore, Rebecca Gelman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2017
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast CancerMaura N Dickler, Sara M Tolaney, Hope S Rugo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP systemClifford A Hudis, William E Barlow, Joseph P Costantino, et al.
Breast Cancer Research and Treatment|June 15, 2006
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806Mercedes Rincon, Gloria Broadwater, Lyndsay Harris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancerJ Baselga, D Tripathy, J Mendelsohn, et al.
Journal of Cancer Survivorship : Research and Practice|June 12, 2014
Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901Leigh Anne Faul, Gheorghe Luta, Vanessa Sheppard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2015
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)Hope S Rugo, William T Barry, Alvaro Moreno-Aspitia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancerAna M Gonzalez-Angulo, Katherine Stemke-Hale, Shana L Palla, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2016
Research needs in breast cancerF Cardoso, N Harbeck, C H Barrios, et al.
Seminars in Oncology|September 11, 1999
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancerJ Baselga, D Tripathy, J Mendelsohn, et al.
Pageof 43